PCVX — Vaxcyte Cashflow Statement
0.000.00%
Last trade - 00:00- $6.62bn
- $5.54bn
- 39
- 21
- 76
- 42
Annual cashflow statement for Vaxcyte, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -50.3 | -89.2 | -100 | -223 | -402 |
| Depreciation | |||||
| Non-Cash Items | -2.01 | 5.91 | 13.9 | 37.6 | 21 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.91 | 35.3 | -37 | 12.7 | 81.3 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -47.1 | -46.6 | -121 | -171 | -297 |
| Capital Expenditures | -1.2 | -1.16 | -6.55 | -5.85 | -67.9 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | 0.05 | -206 | 80.4 | -705 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -1.2 | -1.1 | -212 | 74.6 | -773 |
| Financing Cash Flow Items | -1.1 | -3.37 | 0 | -0.861 | -3.88 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 41.6 | 375 | 17.8 | 862 | 640 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -7.11 | 327 | -316 | 766 | -437 |